DrugPatentWatch Database Preview
Details for Patent: 6,667,314
Which drugs does patent 6,667,314 protect, and when does it expire?
Patent 6,667,314 protects SELZENTRY and is included in two NDAs.
This patent has ninety-six patent family members in fifty-five countries.
Summary for Patent: 6,667,314
| Title: | Tropane derivatives useful in therapy |
| Abstract: | The present invention provides compounds of the formula: ##STR1## wherein R.sup.1 is C.sub.3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C.sub.1-6 alkyl optionally substituted by one or more fluorine atoms, or C.sub.3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R.sup.2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds. |
| Inventor(s): | Perros; Manoussos (County of Kent, GB), Price; David Anthony (County of Kent, GB), Stammen; Blanda Luzia Christa (County of Kent, GB), Wood; Anthony (County of Kent, GB) |
| Assignee: | Pfizer, Inc. (New York, NY) |
| Application Number: | 09/865,950 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Process; |
Drugs Protected by US Patent 6,667,314
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | Start Trial | ||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-003 | Nov 4, 2016 | RX | Yes | No | Start Trial | Start Trial | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | Start Trial | ||
| Viiv Hlthcare | SELZENTRY | maraviroc | TABLET;ORAL | 022128-004 | Nov 4, 2016 | RX | Yes | No | Start Trial | Start Trial | Y | Y | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,667,314
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0015835 | Jun 27, 2000 |
International Family Members for US Patent 6,667,314
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1965 | Start Trial | |||
| Argentina | 028622 | Start Trial | |||
| Argentina | 060159 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
